 | Related Articles |
[Lenalidomide nephrotoxicity].
Bull Cancer. 2016 May;103(5):499-506
Authors: Kheder El-Fekih R, Izzedine H
Abstract
The introduction of lenalidomide into the therapeutic arsenal of hematologic malignancies has represented an important step forward in the management of multiple myeloma. However, its use is associated with several toxicities including kidney injury. The present review examines the drug's pharmacokinetics, discusses the main adverse renal effects that are associated with lenalidomide treatment, and makes recommendations for dosage adjustment in patients with underlying renal impairment.
PMID: 26927826 [PubMed - indexed for MEDLINE]
http://ift.tt/2jt3oVf
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου